ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Options Flow

Live Options Flow

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P TSX Capped Composite...
35.73
0.59%
US Tech 100
17,636.00
0.19%
S&P 500
5,213.06
0.49%
US Dollar vs CAD
1.36805
-0.34%
Bitcoin
62,350.90
1.90%
Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. AMEX
  6. Matinas Biopharma Holdings Inc (MTNB)

  7. Matinas Biopharma Holdings Inc (MTNB) News

MTNB Matinas Biopharma Holdings Inc

0.17755
0.00005 (0.03%)
Last Updated: 14:21:07
Delayed by 15 minutes
Share Name Share Symbol Market Stock Type
Matinas Biopharma Holdings Inc MTNB AMEX Common Stock
  Price Change Price Change % Share Price Last Trade
Upgrade Icon
0.00005 0.03% 0.17755 14:21:07
Open Price Low Price High Price Close Price Previous Close
0.18 0.1716 0.1825 0.1775
more quote information »

Recent News

Date Time Source Heading
5/07/202407:00GLOBEMatinas BioPharma’s LNC Platform for the Delivery of Small..
5/02/202406:00GLOBEMatinas BioPharma to Webcast Conference Call to Discuss..
4/30/202407:00GLOBEIn Vivo Efficacy of Matinas BioPharma’s Oral MAT2203 in..
4/03/202407:30GLOBEMatinas BioPharma Prices $10 Million Registered Direct..
3/27/202415:05GLOBEMatinas BioPharma Reports 2023 Financial Results and..
3/25/202407:00GLOBEMatinas BioPharma Announces Positive in vivo Safety Data..
3/22/202408:15GLOBEThree Patients with Invasive Fusarium Infection in Matinas..
3/22/202405:30GLOBEMatinas BioPharma Regains Compliance with NYSE American..
2/26/202407:05EDGAR2Form 8-K - Current report
2/26/202407:00GLOBEMatinas BioPharma Provides Positive Outcomes Update on the..
2/20/202406:35EDGAR2Form 8-K - Current report
2/20/202406:30GLOBEMatinas BioPharma Successfully Reaches Agreement with FDA..
1/09/202406:30EDGAR2Form 8-K - Current report
1/03/202406:00GLOBEMatinas BioPharma to Present at Biotech Showcase 2024
12/27/202306:40EDGAR2Form 8-K - Current report
12/27/202306:30GLOBEMatinas BioPharma Demonstrates in vivo Biological Activity..
12/21/202306:40EDGAR2Form 8-K - Current report
12/21/202306:30GLOBEMatinas BioPharma Provides Update to MAT2203 Regulatory and..
12/15/202320:46EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12/15/202320:46EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12/15/202320:46EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12/15/202320:46EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12/15/202320:46EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12/15/202320:46EDGAR2Form 4 - Statement of changes in beneficial ownership of..
11/20/202306:30EDGAR2Form 8-K - Current report
11/09/202316:25EDGAR2Form 8-K - Current report
11/08/202315:06EDGAR2Form 8-K - Current report
11/08/202315:05GLOBEMatinas BioPharma Reports Third Quarter 2023 Financial..
11/08/202315:01EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
11/07/202306:30GLOBEMatinas BioPharma Announces Positive in vivo Efficacy..
11/03/202315:49EDGAR2Form 4 - Statement of changes in beneficial ownership of..
11/02/202316:20EDGAR2Form 8-K - Current report
11/01/202306:00GLOBEMatinas BioPharma to Webcast Conference Call to Discuss..
10/11/202309:25APSBiotech Catches Massive Premarket Bid
10/11/202306:30GLOBEPatient with Candida krusei Infection in Matinas BioPharma’s..
9/28/202306:00GLOBEMatinas BioPharma to Present at Two Investment Conferences..
9/27/202306:00GLOBEMatinas BioPharma to Feature MAT2203 in a Pipeline..
9/22/202316:25EDGAR2Form 8-K - Current report
9/22/202316:25GLOBEMatinas BioPharma Announces Notification of NYSE American..
9/21/202308:35GLOBEDawson James Securities Announces October Date for 8th..
9/20/202306:30EDGAR2Form 8-K - Current report
9/19/202316:25EDGAR2Form DEF 14A - Other definitive proxy statements
9/08/202316:15EDGAR2Form PRE 14A - Other preliminary proxy statements
9/06/202306:00GLOBEMatinas BioPharma to Participate in the H.C. Wainwright..
8/22/202306:30GLOBEMatinas BioPharma Announces Publication of Results from the..
8/09/202315:06EDGAR2Form 8-K - Current report
8/09/202315:05GLOBEMatinas BioPharma Reports Second Quarter 2023 Financial..
8/09/202315:02EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
8/02/202306:00GLOBEMatinas BioPharma to Participate in the BTIG Virtual..
7/26/202307:00GLOBEMatinas BioPharma to Webcast Conference Call to Discuss..

Your Recent History

AMEX
MTNB
Matinas Biopharma
Delayed Upgrade Clock
ADVFN Logo

Canada
Company
Business
Popular
Get The App

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved